NO944853L - Glukagonlignende peptid og insulinotropinderivater - Google Patents

Glukagonlignende peptid og insulinotropinderivater

Info

Publication number
NO944853L
NO944853L NO944853A NO944853A NO944853L NO 944853 L NO944853 L NO 944853L NO 944853 A NO944853 A NO 944853A NO 944853 A NO944853 A NO 944853A NO 944853 L NO944853 L NO 944853L
Authority
NO
Norway
Prior art keywords
derivatives
insulinotropin
truncated
glp
glucagon
Prior art date
Application number
NO944853A
Other languages
English (en)
Norwegian (no)
Other versions
NO944853D0 (no
Inventor
Glenn C Andrews
Gaston O Daumy
Michael L Francoeur
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO944853D0 publication Critical patent/NO944853D0/no
Publication of NO944853L publication Critical patent/NO944853L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO944853A 1992-06-15 1994-12-14 Glukagonlignende peptid og insulinotropinderivater NO944853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89907392A 1992-06-15 1992-06-15
PCT/US1993/003388 WO1993025579A1 (en) 1992-06-15 1993-04-14 Glucagon-like peptide and insulinotropin derivatives

Publications (2)

Publication Number Publication Date
NO944853D0 NO944853D0 (no) 1994-12-14
NO944853L true NO944853L (no) 1994-12-14

Family

ID=25410453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944853A NO944853L (no) 1992-06-15 1994-12-14 Glukagonlignende peptid og insulinotropinderivater

Country Status (19)

Country Link
EP (2) EP0646128A1 (zh)
JP (1) JP2575298B2 (zh)
KR (1) KR0154880B1 (zh)
CN (1) CN1057098C (zh)
AU (1) AU671117B2 (zh)
BR (1) BR9306551A (zh)
CA (1) CA2138161C (zh)
CZ (1) CZ315594A3 (zh)
FI (1) FI932722A (zh)
HR (1) HRP930993A2 (zh)
HU (2) HUT64367A (zh)
IL (1) IL105928A0 (zh)
MX (1) MX9303554A (zh)
NO (1) NO944853L (zh)
PL (1) PL176007B1 (zh)
RU (1) RU2128663C1 (zh)
SK (1) SK155694A3 (zh)
WO (1) WO1993025579A1 (zh)
YU (1) YU41493A (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996017941A2 (en) * 1994-12-07 1996-06-13 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2335066T3 (es) 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
IL143481A0 (en) * 1998-12-07 2002-04-21 Sod Conseils Rech Applic Glp-1 analogues
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
BR0307727A (pt) 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005066207A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
US9296805B2 (en) * 2009-06-18 2016-03-29 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
SI3297653T1 (sl) 2015-05-22 2022-01-31 The Board Of Trustees Of Leland Stanford Junior University Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1
EP3463424A1 (en) * 2016-06-02 2019-04-10 Indiana University Research & Technology Corporation Glucagon-like peptide-1-t3 conjugates
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929217T2 (de) * 1989-03-20 2000-11-30 The General Hospital Corp., Boston Insulinotropes hormon
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
ES2087323T3 (es) * 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
EP0646128A1 (en) 1995-04-05
BR9306551A (pt) 1998-09-15
AU4027593A (en) 1994-01-04
HUT64367A (en) 1993-12-28
FI932722A (fi) 1993-12-16
YU41493A (sh) 1996-10-18
KR0154880B1 (ko) 1998-10-15
NO944853D0 (no) 1994-12-14
MX9303554A (es) 1994-06-30
HU211498A9 (en) 1995-11-28
RU94046251A (ru) 1996-10-27
JPH07504679A (ja) 1995-05-25
JP2575298B2 (ja) 1997-01-22
AU671117B2 (en) 1996-08-15
WO1993025579A1 (en) 1993-12-23
HRP930993A2 (en) 1996-12-31
PL176007B1 (pl) 1999-03-31
KR950701937A (ko) 1995-05-17
HU9301739D0 (en) 1993-09-28
SK155694A3 (en) 1995-05-10
CN1085913A (zh) 1994-04-27
IL105928A0 (en) 1993-10-20
CN1057098C (zh) 2000-10-04
CA2138161C (en) 2003-10-21
RU2128663C1 (ru) 1999-04-10
EP0969016A2 (en) 2000-01-05
CA2138161A1 (en) 1993-12-23
FI932722A0 (fi) 1993-06-14
CZ315594A3 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
NO944853L (no) Glukagonlignende peptid og insulinotropinderivater
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
ATE164852T1 (de) Glp-1-analoga verwendbar in der diabetesbehandlung
ATE480259T1 (de) Intranasale verabreichung von glucose- regulierenden peptiden
EP0378364A3 (en) Analogues of pf4 and fragments thereof, and pharmaceutical compositions containing them
NO942840L (no) Antitrombotiske polypeptider som antagonister for binding av VWF til blodplater eller til subendotel
CA2155933A1 (en) Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
NO974269L (no) Lipofile peptidhormonderivater
DE69836199D1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
ES2153362T3 (es) Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos.
NO940436D0 (no) Forlenget avgivelse av peptider
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
SE9901379D0 (sv) Receptor structures
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
ATE143009T1 (de) Neue heterocyclische carbonsäuren
ATE505199T1 (de) Pharmazeutische, kosmetische oder therapeutische zusammensetzungen enthaltend peptide mit dem motiv arg-gly-ser
ATE359296T1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DE10033195A1 (de) Bifunktionale Fusionsproteine aus Hirudin und TAP
DE2442995A1 (de) Proteasefreie kallikreinloesungen, ein verfahren zu ihrer herstellung aus gereinigtem kallikrein und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application